TriangleBrentuximab Vedotin (NCT05039073)
Brentuximab Vedotin trial for Recurrent Classic Hodgkin Lymphoma (NCT05039073). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people aged at least 12 with relapsed or refractory classical Hodgkin lymphoma after a qualifying brentuximab-containing or checkpoint-inhibitor regimen, but not both. Prior stem-cell transplantation is excluded.
The idea: combine brentuximab vedotin, which delivers a toxin to CD30-bearing cells, with nivolumab, which releases an immune brake. Both are infused every three weeks for up to sixteen cycles. Responding patients may stop after at least four cycles to pursue transplantation. Researchers measure responses.
This phase 2 study plans 46 patients. Emory’s Kristie Blum leads it; two Atlanta sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.